Combination therapeutics in complex diseases

The biological redundancies in molecular networks of complex diseases limit the efficacy of many single drug therapies. Combination therapeutics, as a common therapeutic method, involve pharmacological intervention using several drugs that interact with multiple targets in the molecular networks of diseases and may achieve better efficacy and/or less toxicity than monotherapy in practice. The development of combination therapeutics is complicated by several critical issues, including identifying multiple targets, targeting strategies and the drug combination. This review summarizes the current achievements in combination therapeutics, with a particular emphasis on the efforts to develop combination therapeutics for complex diseases.

[1]  Michael Hallek,et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.

[2]  Y. Bang,et al.  Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. , 2008, International journal of oncology.

[3]  J. Dancey,et al.  Strategies for optimizing combinations of molecularly targeted anticancer agents , 2006, Nature Reviews Drug Discovery.

[4]  Hyunju Lee,et al.  Predicting Drug-Target Interactions Using Drug-Drug Interactions , 2013, PloS one.

[5]  Mohieddin Jafari,et al.  Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database , 2015, Briefings Bioinform..

[6]  Nobuyoshi Sugaya,et al.  Training Based on Ligand Efficiency Improves Prediction of Bioactivities of Ligands and Drug Target Proteins in a Machine Learning Approach , 2013, J. Chem. Inf. Model..

[7]  Liang Liu,et al.  Network-based drug discovery by integrating systems biology and computational technologies , 2012, Briefings Bioinform..

[8]  Russ B. Altman,et al.  Knowledge-based Fragment Binding Prediction , 2014, PLoS Comput. Biol..

[9]  Shao Li,et al.  Tetramethylpyrazine identified by a network pharmacology approach ameliorates methotrexate-induced oxidative organ injury. , 2015, Journal of ethnopharmacology.

[10]  Remy Chait,et al.  Drug interactions modulate the potential for evolution of resistance , 2008, Proceedings of the National Academy of Sciences.

[11]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[12]  D. Sharples.  Factors affecting the binding of tricyclic tranquillizers and antidepressants to human serum albumin , 1976, The Journal of pharmacy and pharmacology.

[13]  Jun S. Liu,et al.  Genetics of rheumatoid arthritis contributes to biology and drug discovery , 2013 .

[14]  K. Retting,et al.  BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation , 2009, Development.

[15]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[16]  D. Hartl,et al.  Accelerated evolution of resistance in multidrug environments , 2008, Proceedings of the National Academy of Sciences.

[17]  Aspire Investigators,et al.  Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .

[18]  S. Jaffrey,et al.  Intra-axonal Translation of SMAD1/5/8 Mediates Retrograde Regulation of Trigeminal Ganglia Subtype Specification , 2012, Neuron.

[19]  J. Tilly,et al.  Bone morphogenetic protein 4 promotes mammalian oogonial stem cell differentiation via Smad1/5/8 signaling. , 2013, Fertility and sterility.

[20]  Michael J Ackerman,et al.  Nature Genetics Advance Online Publication Genetic Association Study of Qt Interval Highlights Role for Calcium Signaling Pathways in Myocardial Repolarization , 2022 .

[21]  D. V. Von Hoff,et al.  Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. , 2014, The New England journal of medicine.

[22]  Thomas Lengauer,et al.  Computational methods for biomolecular docking. , 1996, Current opinion in structural biology.

[23]  S. Vilar,et al.  High-Throughput Methods for Combinatorial Drug Discovery , 2013, Science Translational Medicine.

[24]  C. Boni,et al.  Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. , 2014, The New England journal of medicine.

[25]  J. Greene,et al.  Combination drugs--hype, harm, and hope. , 2011, The New England journal of medicine.

[26]  Alex Bateman,et al.  The rise and fall of supervised machine learning techniques , 2011, Bioinform..

[27]  G. Rodan.  Bone homeostasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  David Z. Chen,et al.  Architecture of the human regulatory network derived from ENCODE data , 2012, Nature.

[29]  Michael Schroeder,et al.  Prediction of drug gene associations via ontological profile similarity with application to drug repositioning. , 2015, Methods.

[30]  R. Darouiche,et al.  Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI) , 2015, The Lancet.

[31]  Michael L. Wang,et al.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.

[32]  Roger Guimerà,et al.  A Network Inference Method for Large-Scale Unsupervised Identification of Novel Drug-Drug Interactions , 2013, PLoS Comput. Biol..

[33]  P. Serruys,et al.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials , 2003 .

[34]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[35]  Xiang-Pei Li,et al.  Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. , 2013, International immunopharmacology.

[36]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[37]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[38]  R. Glen,et al.  Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.

[39]  G. Mills,et al.  Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling* , 2004, Journal of Biological Chemistry.

[40]  Roland Baron,et al.  WNT signaling in bone homeostasis and disease: from human mutations to treatments , 2013, Nature Medicine.

[41]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[42]  Tamas Koncz,et al.  Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial , 2013, The Lancet.

[43]  J. Groten,et al.  Toxicology of simple and complex mixtures. , 2001, Trends in pharmacological sciences.

[44]  Christos Hatzis,et al.  Reproducibility of research and preclinical validation: problems and solutions , 2013, Nature Reviews Clinical Oncology.

[45]  S. Mandrekar,et al.  A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321 , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  M. Ramanathan,et al.  Network‐Based Approaches in Drug Discovery and Early Development , 2013, Clinical pharmacology and therapeutics.

[47]  Andreas Bender,et al.  Ligand-Target Prediction Using Winnow and Naive Bayesian Algorithms and the Implications of Overall Performance Statistics , 2008, J. Chem. Inf. Model..

[48]  D. Geerts,et al.  Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target , 2015, BMC Cancer.

[49]  C. Punt,et al.  Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group , 2015, The Lancet.

[50]  K. Kolaja,et al.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes , 2011, Nature Reviews Drug Discovery.

[51]  L. Chin,et al.  Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.

[52]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[53]  N J Wald,et al.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials , 2003, BMJ : British Medical Journal.

[54]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[55]  M. Ellis,et al.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. , 2015, The New England journal of medicine.

[56]  O. Vignaux,et al.  Pancreatic atrophy--a new late toxic effect of sorafenib. , 2013, The New England journal of medicine.

[57]  Yang Xie,et al.  A community computational challenge to predict the activity of pairs of compounds , 2014, Nature Biotechnology.

[58]  Bhanu P. Jena,et al.  Journal of Cellular and Molecular Medicine , 2014, Journal of Cellular and Molecular Medicine.

[59]  R. Kishony,et al.  Antibiotic interactions that select against resistance , 2007, Nature.

[60]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[61]  Christian Jacques,et al.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. , 2014, The New England journal of medicine.

[62]  J J Martinez-Irujo,et al.  Analysis of the combined effect of two linear inhibitors on a single enzyme. , 1998, The Biochemical journal.

[63]  Gerard J. Kleywegt,et al.  A chemogenomics view on protein-ligand spaces , 2009, BMC Bioinformatics.

[64]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[65]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[66]  María J. Vicent,et al.  Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. , 2009, Advanced drug delivery reviews.

[67]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[68]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[69]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[70]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[71]  Richard E. Turner,et al.  A multi-label approach to target prediction taking ligand promiscuity into account , 2015, Journal of Cheminformatics.

[72]  K. W. Jung,et al.  A series of case studies: practical methodology for identifying antinociceptive multi-target drugs. , 2012, Drug discovery today.

[73]  F. Bazzoli,et al.  A combination of eicosapentaenoic acid-free fatty acid, epigallocatechin-3-gallate and proanthocyanidins has a strong effect on mTOR signaling in colorectal cancer cells. , 2014, Carcinogenesis.

[74]  S. Deeks,et al.  Treatment of antiretroviral-drug-resistant HIV-1 infection , 2003, The Lancet.

[75]  F. Prósper,et al.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. , 2013, The New England journal of medicine.

[76]  Remy Chait,et al.  Optimal Drug Synergy in Antimicrobial Treatments , 2010, PLoS Comput. Biol..

[77]  P. Emery,et al.  Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial , 2014, The Lancet.

[78]  J. Bergh,et al.  Thyroid hormone inactivation in gastrointestinal stromal tumors. , 2014, The New England journal of medicine.

[79]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[80]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[81]  G. Hortobagyi,et al.  Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. , 2002, Cancer research.

[82]  M. Wehling,et al.  The translatability of animal models for clinical development: biomarkers and disease models. , 2010, Current opinion in pharmacology.

[83]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[84]  W. Szybalski,et al.  Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. , 1954, Journal of bacteriology.

[85]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[86]  A. Good,et al.  3-D pharmacophores in drug discovery. , 2001, Current pharmaceutical design.

[87]  G. Dranitsaris,et al.  Biosimilars of Biological Drug Therapies , 2011, Drugs.

[88]  C. Deng,et al.  Ubiquitin Ligase Smurf1 Controls Osteoblast Activity and Bone Homeostasis by Targeting MEKK2 for Degradation , 2005, Cell.

[89]  Brendan H. Lee,et al.  Dimorphic effects of Notch signaling in bone homeostasis , 2008, Nature Medicine.

[90]  M. Edavalath,et al.  Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension , 2012, Patient preference and adherence.

[91]  Wei Xiao,et al.  Quantitative modeling of dose–response and drug combination based on pathway network , 2015, Journal of Cheminformatics.

[92]  David Cunningham,et al.  Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles , 2013, The Lancet.

[93]  J. Baselga,et al.  Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial , 2014, Clinical Cancer Research.

[94]  C. I. Bliss.  The calculation of microbial assays. , 1956, Bacteriological reviews.

[95]  Christian Munck,et al.  Prediction of resistance development against drug combinations by collateral responses to component drugs , 2014, Science Translational Medicine.

[96]  John A. Pickrell,et al.  Casarett and Doull's toxicology: The basic science of poisons , 1996 .

[97]  D. L. Klayman,et al.  Qinghaosu (artemisinin): an antimalarial drug from China. , 1985, Science.

[98]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[99]  S. Ogawa,et al.  The genomic landscape of nasopharyngeal carcinoma , 2014, Nature Genetics.

[100]  James Inglese,et al.  Mitigating risk in academic preclinical drug discovery , 2015, Nature Reviews Drug Discovery.

[101]  R. Sahoo,et al.  Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. , 2014, The New England journal of medicine.

[102]  Wan-ying Wu,et al.  Combined Salvianolic Acid B and Ginsenoside Rg1 Exerts Cardioprotection against Ischemia/Reperfusion Injury in Rats , 2015, PloS one.

[103]  S. Loewe.  The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[104]  Yanli Wang,et al.  Developing and validating predictive decision tree models from mining chemical structural fingerprints and high–throughput screening data in PubChem , 2008, BMC Bioinformatics.

[105]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[106]  M. Prichard,et al.  A three-dimensional model to analyze drug-drug interactions. , 1990, Antiviral research.

[107]  S. Loewe,et al.  Die quantitativen Probleme der Pharmakologie , 1928 .

[108]  L. Chao.  An unusual interaction between the target of nalidixic acid and novobiocin , 1978, Nature.

[109]  G. Klebe.  Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.

[110]  Tanya M. Teslovich,et al.  Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility , 2014, Nature Genetics.

[111]  Ronan M. T. Fleming,et al.  A community-driven global reconstruction of human metabolism , 2013, Nature Biotechnology.

[112]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[113]  Carole Ober,et al.  The genetics of asthma and allergic disease: a 21st century perspective , 2011, Immunological reviews.

[114]  R. Perez-soler,et al.  Treatment of non-small-cell lung cancer with erlotinib or gefitinib. , 2011, The New England journal of medicine.

[115]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[116]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[117]  Wei Chen,et al.  Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study , 2014, The Lancet.

[118]  D. Adu,et al.  Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial , 2013, The Lancet.

[119]  Hao Ding,et al.  Similarity-based machine learning methods for predicting drug-target interactions: a brief review , 2014, Briefings Bioinform..

[120]  Oliver Werz,et al.  Multi-target approach for natural products in inflammation. , 2014, Drug discovery today.

[121]  L. Blonde,et al.  Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study , 2015, The Lancet.